Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD

(2022) Lu Zhang et al.   LEUKEMIA & LYMPHOMA

Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation

(2021) Beata Ostrowska et al.   LEUKEMIA & LYMPHOMA

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy

(2021) Sudipto Mukherjee et al.   Blood Advances

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

(2020) Frits van Rhee et al.   Lancet Haematology

The Role of Interleukin-6 in Castleman Disease

(2018) Kazuyuki Yoshizaki et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

(2018) Frits van Rhee et al.   BLOOD

Idiopathic multicentric Castleman's disease: a systematic literature review

(2016) Amy Y Liu et al.   Lancet Haematology

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

(2013) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

The clinical spectrum of Castleman's disease

(2012) Angela Dispenzieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY